The association of topoisomerase 2α expression with prognosis in surgically resected non-small cell lung cancer (NSCLC) patients

Journal of Thoracic Disease

Volumn 4, Issue 4, 2012, Pages 352-357

  Erguden, Hulya Çelenk ^a   Koksal, Deniz ^a   Demirag, Funda ^a   Bayiz, Hulya ^a   Mutluay, Neslihan ^a   Berktas, Bahadir ^a   Berkoglu, Mine ^a  

^a Ataturk Chest Disease and Thoracic Surgery Education and Research Hospital Ankara   (Turkey)

Author keywords

Non small cell lung cancer; Prognosis; Topoisomerase 2

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); PARAFFIN; TOPOISOMERASE 2ALPHA; UNCLASSIFIED DRUG;

ADULT; AGE; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SIZE; CANCER SURGERY; CANCER SURVIVAL; CANCER TISSUE; CELL NUCLEUS; CORRELATIONAL STUDY; CYTOPLASM; DISEASE SEVERITY; FEMALE; FOLLOW UP; GENDER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LOBECTOMY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG RESECTION; LUNG SQUAMOUS CELL CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; PROTEIN EXPRESSION; SMOKING; TUMOR DIFFERENTIATION;

EID: 84866875590     PISSN: 20721439     EISSN: 20776624     Source Type: Journal    
DOI: 10.3978/j.issn.2072-1439.2012.08.04     Document Type: Article

References (20)

1. Brundage MD, Mackillop WJ. Prognostic factors in thoracic malignancies. In: Goldstraw P. eds. IASLC Manual - Staging Manual in Thoracic Oncology. Orange Park, FL, USA: Editorial Rx Press. 2009:129-40.
2. Gospodarowicz MK, O'Sullivan B, Koh ES. Prognostic factors: Principles and applications. In: Peter Goldstraw. eds. IASLC Manual - Staging Manual in Thoracic Oncology. Orange Park, FL, USA: Editorial Rx Press. 2009:111-28.
3. Brundage MD, Mackillop WJ. Lung cancer. In: Gospodarowicz MK HD, Hutter RVP, O'Sullivan B, et al. eds. Prognostic Factors in Cancer. New York: Wiley-Liss, 2001:3S 1-70.
4. Brundage MD, Davies D, Mackillop WJ. Prognostic factors in non-small cell lung cancer: a decade of progress. Chest 2002; 122:1037-57.
5. Heck MM, Earnshaw WC. Topoisomerase II: A specific marker for cell proliferation. J Cell Biol 1986;103:2569-81.
6. Froelich-Ammon SJ, Osheroff N. Topoisomerase poisons: harnessing the dark side of enzyme mechanism.J Biol Chem 1995;270:21429-32.
7. Syahruddin E, Oguri T, Takahashi T, et al. Differential expression of DNA topoisomerase II alpha and II beta genes between small cell and non-small cell lung cancer.JpnJ Cancer Res 1998;89:855-61.
8. Guinee DG Jr, Holden JA, Benfield JR, et al. Comparison of DNA topoisomerase II alpha expression in small cell and nonsmall cell carcinoma of the lung. In search of a mechanism of chemotherapeutic response. Cancer 1996;78:729-35.
9. Dingemans AM, Witlox MA, Stallaert RA, et al. Expression of DNA topoisomerase I alpha and topoisomerase Ilbeta genes predicts survival and response to chemotherapy in patients with small cell lung cancer. Clin Cancer Res 1999;5:2048-58.
10. Detterbeck FC, Boffa DJ, Tanoue LT. The new lung cancer staging system. Chest 2009;136:260-71.
11. Woessner RD, Mattern MR, Mirabelli CK, et al. Proliferation-and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells. Cell Growth Differ 1991;2:209-14.
12. Giaccone G, van Ark-Otte J, Scagliotti G, et al. Differential expression of DNA topoisomerases in non-small cell lung cancer and normal lung. Biochim Biophys Acta 1995;1264:337-46.
13. Mirski SE, Voskoglou-Nomikos T, Young LC, et al. Simultaneous quantitation of topoisomerase II alpha and beta isoform mRNAs in lung tumor cells and normal and malignant lung tissue. Lab Invest 2000;80:787-95.
14. Dingemans AC, van Ark-Otte J, Span S, et al. Topoisomerase Ilalpha and other drug resistance markers in advanced non-small cell lung cancer. Lung Cancer 2001;32:117-28.
15. Kreisholt J, Sorensen M, Jensen PB, et al. Inununohistochemical detection of DNA topoisomerase Ilalpha, P-glycoprotein and multidrug resistance protein (MRP) in small-cell and non-small-cell lung cancer. Br J Cancer 1998;77:1469-73.
16. Giaccone G, Gazdar AF, Beck H, et al. Multidrug sensitivity phenotype of human lung cancer cells associated with topoisomerase II expression. Cancer Res 1992;52:1666-74.
17. Stathopoulos GP, Kapranos N, Manolopoulos L, et al. Topoisomerase II alpha expression in squamous cell carcinomas of the head and neck. Anticancer Res 2000;20:177-82.
18. Liu D, Huang CL, Kameyama K, Hayashi E, et al. Topoisomerase Ilalpha gene expression is regulated by the p53 tumor suppressor gene in nonsmall cell lung carcinoma patients. Cancer 2002;94:2239-47.
19. Nakopoulou L, Lazaris AC, Kavantzas N, et al. DNA topoisomerase Ilalpha immunoreactivity as a marker of tumor aggressiveness in invasive breast cancer. Pathobiology 2000;68:137-43.
20. Chiappori AA, Zheng Z, Chen T, et al. Features of potentially predictive biomarkers of chemotherapeutic efficacy in small cell lung cancer. J Thorac Oncol 2010;5:484-90.